ライフサイエンスコーパス: second-line therapy

1 nation with mesenchymal stromal cells (MSCs; second-line therapy).

2 lecular mechanism of resistance and to guide second-line therapy.

3 quiring a switch to protease inhibitor-based second-line therapy.

4 gression received the alternative regimen as second-line therapy.

5 , gefitinib, or pemetrexed is recommended as second-line therapy.

6 milar toxicity rates and are appropriate for second-line therapy.

7 l use of either irinotecan or oxaliplatin as second-line therapy.

8 tients received irinotecan-based regimens as second-line therapy.

9 taxel and ifosfamide plus cisplatin (TIP) as second-line therapy.

10 in the future, and so will remain as a weak second-line therapy.

11 Half the cohort received ZD1839 as second-line therapy.

12 portions of patients in both groups received second-line therapy.

13 eekly docetaxel and trastuzumab as first- or second-line therapy.

14 taxel and ifosfamide plus cisplatin (TIP) as second-line therapy.

15 alive and in remission following successful second-line therapy.

16 st dose of etoposide-containing frontline or second-line therapy.

17 ears), transplantation-eligible patients for second-line therapy.

18 ietic stem cell transplantation as a part of second-line therapy.

19 oids or become dependent on them and require second-line therapy.

20 avir but is at greater risk of resistance in second-line therapy.

21 s, developed acquired resistance, and failed second-line therapy.

22 s, but has not previously been assessed as a second-line therapy.

23 or HCC, but relatively few patients received second-line therapy.

24 rides, and polyols (FODMAP) diet reserved as second-line therapy.

25 the full study cohort, 871 (20.7%) received second-line therapy.

26 ay influence clinician and patient choice of second-line therapy.

27 late diagnosis, and multi-antiarrhythmic or second-line therapy.

28 Tenofovir was noninferior to zidovudine as second-line therapy.

29 t-line therapy, or tramadol or duloxetine as second-line therapy.

30 ongest OS was achieved when TARE was part of second-line therapy.

31 cythaemia vera without splenomegaly who need second-line therapy.

32 delines that help in choosing an appropriate second-line therapy.

33 examethasone independently prolonged time to second-line therapy.

34 ming virological failure before switching to second-line therapy.

35 d Drug Administration of PD-1 inhibitors for second-line therapy.

36 ent treatment with nilotinib or dasatinib as second-line therapy.

37 ear or less, and progressive disease despite second-line therapy.

38 failure of these drugs; there is no approved second-line therapy.

39 irst-line setting and anetumab ravtansine as second-line therapy.

40 ained efficacy in BRAF(V600E)-mutated ECD as second-line therapy.

41 mproved patient counseling and selection for second-line therapy.

42 was overall survival since the initiation of second-line therapy.

43 to evaluate the efficacy of CA as first- or second-line therapy.

44 lar definitions are provided for response to second-line therapy.

45 patient who developed t-AML/MDS did so after second-line therapy.

46 n receptor agonists (TPO-RAs) as options for second-line therapy.

47 00 mg/m(2) once every 21 days) as predefined second-line therapy.

48 ibed for treatment, as well as candidacy for second-line therapies.

49 p alternative first-line regimens and better second-line therapies.

50 months, but patients are rarely switched to second-line therapies.

51 and with different criteria for switching to second-line therapies.

52 E) that continued despite initial first- and second-line therapies.

53 ere sputum culture-positive at initiation of second-line therapy, 129 (77%) converted in a median tim

54 opensity score-matched cohort (UDCA 3.77 vs. second-line therapy 4.5 100 persons-year, respectively),

55 Only 45% of patients received second-line therapy (42% in arm A v 47% in arm B, P =.42

56 trate/5-FU combination responded to M-VAC as second-line therapy (42%; 95% CI, 15.2% to 72.3%).

57 mately 75% of patients in both arms received second-line therapy; 58% of rIFL patients received oxali

58 Of 172 patients with known second-line therapy, 85 received CTx (49%); 70, ASCT (41

59 e 135 patients who received the treatment as second-line therapy, 94 were disease-free during follow-

60 ates antitumor activity in metastatic RCC as second-line therapy, a setting where no effective system

61 icantly associated with lower risk of use of second-line therapy (absolute risk difference, -0.22 [95

62 Four cycles of TIP as second-line therapy achieved a durable CR rate in a high

63 buride) or a DPP4i (reference category) as a second line therapy after metformin.

64 Ninety-two patients (35%) needed second-line therapy after a median of 49 months.

65 Patients with AL amyloidosis who need second-line therapy after response to up-front treatment

66 Toremifene is not likely to be used as second-line therapy after tamoxifen failure due to cross

67 first-line ART (ODYSSEY A), or switching to second-line therapy after treatment failure (ODYSSEY B).

68 We repeated analyses to assess switch to second-line therapy among those with consecutively unsup

69 primary biliary cholangitis will qualify for second line therapies and prescribers should be aware of

70 metrexed, have shown significant activity as second-line therapy and are currently being evaluated in

71 Outcomes to second-line therapy and ASCT are superior for late relap

72 This review discusses current second-line therapy and emerging drugs for advanced tran

73 rrelate the percentage of patients receiving second-line therapy and the percentage of patients recei

74 n of nivolumab + ipilimumab as an option for second-line therapy and third-line therapy is discussed.

75 by resistance testing, of the NRTIs used in second-line therapy and treatment outcomes for patients

76 with hepatocellular carcinoma, as first- and second-line therapies, and are awaiting approval by the

77 , considerations in the choice of first- and second-line therapies, and the management of patients af

78 nths for first-line therapy, 17.4 months for second-line therapy, and 12.5 months for third-line ther

79 nths for first-line therapy, 10.0 months for second-line therapy, and 5.9 months for third-line thera

80 of rIFL patients received oxaliplatin-based second-line therapy, and 55% of FOLFOX4 patients receive

81 Treatment with alkylating agents, second-line therapy, and age older than 35 years at trea

82 omisation was stratified by age, response to second-line therapy, and prognostic factors.

83 The advantages and disadvantages of these second line therapies are reviewed.

84 However, second-line therapies are currently recommended only whe

85 nalysis, we have shown that the responses to second-line therapies are durable.

86 Other second-line therapies are limited in their use because o

87 ts offering an improved toxicity profile for second-line therapy are emerging.

88 st follow-up evaluation or the initiation of second-line therapy are included.

89 ons available to ovarian cancer patients for second-line therapy are limited, and knowing that mechan

90 r agents active in ovarian cancer for use as second-line therapy are warranted.

91 n-self-expandable injectable bulking agents (second-line therapies) are equal/superior in terms of ef

92 We assessed the impact of receiving a second-line therapy as a risk factor for decompensated c

93 31%; and (5) suboptimal response to ASCT and second-line therapy as consolidation, 4%.

94 ing clarified and include a lack of standard second-line therapy as well as uncertain benefits for th

95 high-risk patients for closer monitoring and second-line therapies, as well as low-risk patients who

96 py, OS does not significantly differ whether second-line therapy begins with irinotecan or FOLFOX4.

97 s, VEGF receptors, PDGFR-beta, and c-KIT, as second-line therapy both in patients with FGFR2-mutated

98 Only 3% would benefit from the addition of a second line therapy but had not yet been offered medicat

99 mab+atezolizumab, sorafenib, and lenvatinib; second-line therapies: cabozantinib, pembrolizumab, ramu

100 ormation and who have viral suppression with second-line therapy containing a ritonavir-boosted PI ha

101 Recommendation for second-line therapy depends on the extent of the policym

102 Ibuprofen as a second-line therapy did not reduce overall narcotic cons

103 Approximately 22% of patients receiving second-line therapy do not achieve HIV RNA suppression b

104 yclosporine may be an important component of second-line therapy due to its efficacy in controlling u

105 pe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) trial.

106 ith seizure termination after first-line and second-line therapies, episodes of CSE lasting for longe

107 persons-year, respectively), as patients on second-line therapy exhibited advanced liver disease.

108 l therapy; however, no standard approach for second-line therapy exists.

109 In second-line therapy, fludarabine induced a significantly

110 The role of third-generation TKIs as second-line therapy following front-line resistance to s

111 her administered as first-line therapy or as second-line therapy following ICIs with or without chemo

112 t options are essential to selecting optimal second line therapy for patients whose disease progresse

113 st montelukast as an initial therapy or as a second line therapy for refractory disease.

114 AR drug may be used as an alternative second line therapy for treating HER2 + BC.

115 Fenofibrate and bezafibrate are reasonable second-line therapies for dyslipidaemia and in diabetes,

116 Fenofibrate and bezafibrate are reasonable second-line therapies for dyslipidaemia and in diabetes.

117 e the comparative effectiveness of different second-line therapies for mPDAC.

118 PPAR agonists are effective second-line therapies for primary biliary cholangitis.

119 vorin could be considered a standard-of-care second-line therapy for advanced biliary tract cancer.

120 lioma (MPM) has relatively ineffective first/second-line therapy for advanced disease and only 18% fi

121 ment has been accepted widely for the first-/second-line therapy for advanced gastric cancer (AGC).

122 etinib + docetaxel with docetaxel alone as a second-line therapy for advanced KRAS-mutant NSCLC.

123 rospective phase II studies as first-line or second-line therapy for advanced uterine leiomyosarcoma.

124 he regimen is a good choice as first-line or second-line therapy for advanced uterine leiomyosarcoma.

125 cell carcinoma, and nivolumab monotherapy as second-line therapy for all risk groups.

126 o 12 months of rhythm control when used as a second-line therapy for atrial fibrillation in relativel

127 Photodynamic therapy is proposed as a second-line therapy for bacille Calmette-Guerin failures

128 w recommended that splenectomy, the standard second-line therapy for decades, be delayed for at least

129 mprove overall survival versus paclitaxel as second-line therapy for gastric/gastroesophageal junctio

130 agents are used with a protease inhibitor in second-line therapy for human immunodeficiency virus (HI

131 l frontline therapy (hydroxyurea or IFN) and second-line therapy for hydroxyurea-refractory or intole

132 combination regimen was active as first- or second-line therapy for metastatic breast cancer, althou

133 view to update guideline recommendations for second-line therapy for metastatic pancreatic cancer.

134 r receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma

135 y and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCL

136 r trial of biweekly 72 hour 9-AC infusion as second-line therapy for ovarian cancer demonstrates comp

137 The introduction of obeticholic acid as a second-line therapy for patients failing ursodeoxycholic

138 lypeptide capreomycin are all widely used in second-line therapy for patients who develop multidrug-r

139 nt profile of sunitinib as a single agent in second-line therapy for patients with cytokine-refractor

140 Second-line therapy for patients with ES-SCLC includes t

141 reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence

142 e or further-line treatment and suggested as second-line therapy for patients with previous thromboti

143 n-like peptide-1 (GLP1) receptor agonists as second-line therapy for patients with type 2 diabetes.

144 The drug also has been approved as second-line therapy for polycythemia vera (PV).

145 y indicates that gene transfer as a first or second-line therapy for practicing urologists would be w

146 e methotrexate (MTX) remains the mainstay of second-line therapy for rheumatoid arthritis (RA).

147 Lurbinectedin was active as second-line therapy for SCLC in terms of overall respons

148 tiarrhythmic drug therapy both as first- and second-line therapy for the maintenance of sinus rhythm

149 ity and efficacy of sirolimus (rapamycin) as second-line therapy for the treatment of acute graft-ver

150 hionamide (ETA) is an important component of second-line therapy for the treatment of multidrug-resis

151 most practitioners in the USA use IVIG as a second-line therapy for those Kawasaki disease patients

152 Corticosteroids are a second-line therapy for those who do not respond, are in

153 As second-line therapy, fulvestrant should be administered

154 For second-line therapy, gemcitabine plus NAB-paclitaxel sho

155 wo hundred patients potentially eligible for second-line therapy had a PSS of 5.3 (4.6-7.1) months, w

156 Patients who received (90)Y RE as second-line therapy had a slightly longer but not statis

157 Patients who did not receive the alternative second-line therapy had better overall survival with fir

158 tients with organ progression at the time of second-line therapy had inferior survival.

159 carcinoma, patients treated with axitinib as second-line therapy had longer median progression-free s

160 rapy (with at least a partial response after second-line therapy); had received a purine analogue, be

161 n modest but consistent; however, gains from second-line therapies have been disappointing.

162 As second-line therapy, he received interferon alfa-2b (IFN

163 Secondary outcomes included a second-line therapy, hemodynamic support, acute left ven

164 To be a viable option for first- or second-line therapy, however, its cost must approach tha

165 -3.45), and need for multi-antiarrhythmic or second-line therapy (HR: 2.08; 95% CI: 1.45-2.99).

166 orafenib in first-line therapy or placebo in second-line therapy), ICIs were associated with signific

167 atients were considered to have responded to second-line therapy if they satisfied specific criteria,

168 ine therapy in 74 of 442 participants (17%), second-line therapy in 180 participants (41%), and third

169 with a short course of steroids as first- or second-line therapy in 23 patients with primary autoimmu

170 l survival versus placebo plus paclitaxel as second-line therapy in a phase 2 study in Asian patients

171 estigated in combination with doxorubicin as second-line therapy in a randomised phase 3 trial.

172 Apatinib plus HAIC for second-line therapy in advanced HCC with extrahepatic me

173 b (OMA) updosing since its introduction as a second-line therapy in chronic spontaneous urticaria (CS

174 01) with approximately 80% response rates to second-line therapy in either arm, including autologous

175 observed therapy would improve outcomes with second-line therapy in HIV-infected patients for whom fi

176 terferon alfa-2b (IFN-alpha-2b) as first- or second-line therapy in metastatic renal cell cancer (RCC

177 liary cholangitis (PBC), with routine use of second-line therapy in nonresponders to first-line thera

178 r (VEGF) and steroids is currently used as a second-line therapy in patients not responding to monoth

179 Hypoglossal nerve stimulation is a useful second-line therapy in patients who cannot tolerate cont

180 Purpose The standard of care for second-line therapy in patients with advanced pancreatic

181 maintenance therapy after chemotherapy-based second-line therapy in patients with chronic lymphocytic

182 be evaluated in larger studies as first- or second-line therapy in patients with hepatic metastases

183 support the use of trastuzumab deruxtecan as second-line therapy in patients with HER2-positive advan

184 nib, an approved VEGF receptor inhibitor, as second-line therapy in patients with metastatic renal ce

185 e-day topotecan infusion was administered as second-line therapy in patients with previously treated

186 comparing liso-cel with standard of care as second-line therapy in patients with primary refractory

187 nged overall survival versus chemotherapy as second-line therapy in patients with programmed death li

188 nged overall survival versus chemotherapy as second-line therapy in patients with programmed death li

189 lastine, ifosfamide, and cisplatin (VeIP) as second-line therapy in patients with recurrent germ cell

190 body against CD20, combined with ICE or DHAP second-line therapy in patients with relapsed or refract

191 and cycloplegics as first-line methods; the second-line therapy in pseudophakic eyes was laser hyalo

192 l and resistance outcomes of those receiving second-line therapy in resource-limited settings.

193 ties in rechecking VL status or switching to second-line therapy in routine care in Zambia.

194 athy, and multifocal motor neuropathy and as second-line therapy in stiff-person syndrome, dermatomyo

195 ll be used in up to 2 million individuals as second-line therapy in sub Saharan Africa by 2020.

196 and/or when treatment was given as first- or second-line therapy in the metastatic setting.

197 .8% of all patients who received any sort of second-line therapy in the TMZ arm.

198 b could be considered a standard of care for second-line therapy in this post-hydroxyurea patient pop

199 le with highly durable responses suitable as second-line therapy in transplant-ineligible relapsed/re

200 subsequent treatment, with special focus on second-line therapy, in the FIRE-3 trial (FOLFIRI plus c

201 Second line therapies include the leukotriene receptor a

202 Second-line therapies include steroidogenesis inhibitors

203 involves trimethoprim-sulfamethoxazole, with second-line therapies, including atovaquone, dapsone, an

204 Survival and second-line therapy initiation were compared with an his

205 arator), 3 infliximab infusions + 6MP/met as second-line therapy (intervention I), infliximab with ep

206 ntervention II), and 6MP/met + infliximab as second-line therapy (intervention III).

207 Splenectomy is usually proposed when a second-line therapy is needed.

208 r drug, and whether maintaining tenofovir in second-line therapy is non-inferior to switching to zido

209 drug for HI, and utility of octreotide, the second-line therapy, is limited because of poor efficacy

210 r than in 23 ALK-positive controls given any second-line therapy (median overall survival not reached

211 ergence of quinolone resistance, the current second-line therapy, monitoring MICs and evaluating othe

212 Continued cemiplimab plus chemotherapy as second-line therapy (n=64) resulted in a median progress

213 When given with a protease inhibitor in second-line therapy, NRTIs retained substantial virologi

214 Axitinib is a treatment option for second-line therapy of advanced renal cell carcinoma.

215 e-body imaging procedure in combination with second-line therapy of castration-resistant PCa, as well

216 -2 study support the use of ruxolitinib as a second-line therapy of choice for patients with inadequa

217 combination of ganetespib and docetaxel for second-line therapy of patients with advanced adenocarci

218 pean centers, rituximab is now the preferred second-line therapy of warm antibody hemolytic anemia in

219 , had a shorter survival after initiation of second-line therapy on univariate, but not on multivaria

220 t-line therapy with sorafenib or lenvatinib, second-line therapy options for appropriate candidates i

221 line treatment with sorafenib or lenvatinib, second-line therapy options include cabozantinib, regora

222 toring and, when detected, largely preserves second-line therapy options.

223 matory diagnosis and can prevent unnecessary second-line therapies or drug desensitization procedures

224 l lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-ce

225 Patients were randomized to receive standard second-line therapy or avelumab every 2 weeks until prog

226 ts should be confined to first-line therapy, second-line therapy or both.

227 either oxycodone rescue (oxycodone, 5 mg, as second-line therapy) or ibuprofen rescue (ibuprofen, 600

228 eatment effects were similar with first- and second-line therapies (P = 0.16 for heterogeneity).

229 reated patients, compared with patients with second-line therapy (P = 0.011 and P = 0.010, respective

230 the percentage of patients who received any second-line therapy (P =.19).

231 Everolimus is an alternative second-line therapy, particularly in nonfunctioning NETs

232 nd an acceptable safety profile when used as second-line therapy patients with platinum-refractory SC

233 s progression-free survival from the time of second-line therapy (PFS-2) of BTKi vs CIT.

234 Second-line therapy produced only partial responses, and

235 Tenofovir should be continued in second-line therapy, rather than being switched to zidov

236 g the association of a probiotic compound to second-line therapy regimen.

237 isk of death was associated with response to second-line therapy (relative risk, 0.14; 95% CI, 0.05 t

238 rved in 22% and 12% of patients who received second-line therapy, respectively.

239 ant subpopulation, whereas poor adherence or second-line therapy resulted in the reemergence of the d

240 Second-line therapies should be bismuth quadruple therap

241 As second-line therapy, splenectomy and Rituximab are both

242 armacologic strategies, including first- and second-line therapies such as long-acting beta(2)-agonis

243 Antihistamines and second-line therapies such as omalizumab are effective f

244 ents who received the alternative regimen as second-line therapy, the median duration of progression-

245 otably, in patients receiving study drugs as second-line therapy, the mOS was 7.5 months.

246 tected against emergent resistance; starting second-line therapy, the risk of emergent resistance to

247 ory to chemoimmunotherapy or relapsing after second-line therapies, tisagenlecleucel compares favoura

248 Obeticholic acid, the first second-line therapy to be approved for PBC, significantl

249 ay require treatment adjustments including a second-line therapy to improve their outcomes.

250 Second-line therapy typically includes multiagent chemot

251 The median time from ASCT to second-line therapy was 24.3 months.

252 Median follow-up from the time of second-line therapy was 53 months (range, 12-144).

253 Second-line therapy was administered for a median durati

254 higher risk, and if multi-antiarrhythmic or second-line therapy was also required, risk nearly doubl

255 tment with intravenous phenytoin (n=32) as a second-line therapy was associated with a 9 times (95% C

256 Second-line therapy was given to the remaining 100 patie

257 Response to second-line therapy was PD in 34 and SD/MR in 66.

258 Second-line therapy was successful in approximately 60%

259 01 patients with mRCC receiving nivolumab as second-line therapy were evaluated, and 355 eligible pat

260 rug-free interval of 4 or more months during second-line therapy were included.

261 % CI, 0.55 to 0.88; P = .0021) from start of second-line therapy were longer in patients in arm A com

262 prior cytogenetic response on imatinib or on second-line therapy were the only independent predictors

263 be offered to patients, either as initial or second-line therapy when not given in the first-line set

264 cate that ibrutinib will remain reserved for second-line therapy, which may be due to its mechanisms

265 ecan and paclitaxel have similar activity as second-line therapies with regard to response rates and

266 hree hundred three patients received HDCT as second-line therapy with a 2-year PFS of 63% (95% CI, 57

267 owing first-line therapy with durva + treme, second-line therapy with a TKI is recommended.

268 owing first-line treatment with atezo + bev, second-line therapy with a tyrosine kinase inhibitor (TK

269 + bev, and until better data are available, second-line therapy with a tyrosine kinase inhibitor may

270 line therapy with ampicillin and gentamicin, second-line therapy with amikacin and ceftazidime, and m

271 etes, first-line therapy with metformin, and second-line therapy with either sodium-glucose cotranspo

272 We compared second-line therapy with high-dose chemotherapy and auto

273 ed in volume, mice (n = 18) were assigned to second-line therapy with letrozole (100 microg/d; n = 6)

274 Second-line therapy with pembro-GVD is a highly effectiv

275 had first-line treatment failure to receive second-line therapy with tenofovir alafenamide fumarate

276 In this cohort study, second-line therapy with thalidomide was associated with

277 ) or ibuprofen rescue (ibuprofen, 600 mg, as second-line therapy, with oxycodone, 5 mg, reserved for